BioCentury | Jul 24, 2006
Finance

Ebb & Flow

...includes some stem cell work. In 2000, he served as acting president and CEO of CytoTherapeutics...
BioCentury | Nov 1, 2004
Finance

Ebb & Flow

...will remember STEM as a subsidiary of encapsulated cell technology company CytoThera-peutics . In 1999, CytoTherapeutics...
BioCentury | Jun 5, 2000
Finance

Spring loaded

...names down the line. Buyside tracks Genentech (DNA) sold 904,171 shares of StemCells (STEM, formerly CytoTherapeutics...
BioCentury | May 30, 2000
Company News

CytoTherapeutics drug delivery, neurological news

...changed its name to StemCells Inc. and began trading under the NASDAQ ticker symbol STEM. CytoTherapeutics Inc....
BioCentury | Apr 24, 2000
Clinical News

CytoTherapeutics preclinical data

...in vivo. Data were presented at the Society for Experimental Biology meeting in San Diego. CytoTherapeutics Inc....
BioCentury | Mar 20, 2000
Company News

CytoTherapeutics, Genentech gene/cell therapy news

...concerning CTII's encapsulated cell technology research, which DNA had funded through investment in CTII shares. CytoTherapeutics Inc....
BioCentury | Mar 16, 2000
Company News

Cytotherapeutics settles three claims

CTII said it resolved differences with Genentech (DNA) and two Rhode Island agencies, Rhode Island Partnership for Science and Technology and Industrial Recreational Building Authority. The company said it was relieved of the obligation to...
BioCentury | Feb 7, 2000
Company News

CytoTherapeutics management update

CytoTherapeutics Inc. (CTII), Sunnyvale, Calif. Business: Gene/Cell therapy Transition: George Dunbar becomes acting president and CEO, replacing Richard Rose, while remaining acting president of CTII's StemCells Inc. subsidiary Hired: Iris Brest as general counsel, formerly...
BioCentury | Jan 24, 2000
Finance

C'est la vie

...it will appeal. BTGC closed Friday at $15.063 up $1.75 (13 percent) on the week. CytoTherapeutics...
BioCentury | Jan 24, 2000
Tools & Techniques

Cubist: Antibiotic validation

...monoclonal antibodies to isolate human neural stem cells. StemCells (Sunnyvale, Calif.) is a subsidiary of CytoTherapeutics Inc....
Items per page:
1 - 10 of 109
BioCentury | Jul 24, 2006
Finance

Ebb & Flow

...includes some stem cell work. In 2000, he served as acting president and CEO of CytoTherapeutics...
BioCentury | Nov 1, 2004
Finance

Ebb & Flow

...will remember STEM as a subsidiary of encapsulated cell technology company CytoThera-peutics . In 1999, CytoTherapeutics...
BioCentury | Jun 5, 2000
Finance

Spring loaded

...names down the line. Buyside tracks Genentech (DNA) sold 904,171 shares of StemCells (STEM, formerly CytoTherapeutics...
BioCentury | May 30, 2000
Company News

CytoTherapeutics drug delivery, neurological news

...changed its name to StemCells Inc. and began trading under the NASDAQ ticker symbol STEM. CytoTherapeutics Inc....
BioCentury | Apr 24, 2000
Clinical News

CytoTherapeutics preclinical data

...in vivo. Data were presented at the Society for Experimental Biology meeting in San Diego. CytoTherapeutics Inc....
BioCentury | Mar 20, 2000
Company News

CytoTherapeutics, Genentech gene/cell therapy news

...concerning CTII's encapsulated cell technology research, which DNA had funded through investment in CTII shares. CytoTherapeutics Inc....
BioCentury | Mar 16, 2000
Company News

Cytotherapeutics settles three claims

CTII said it resolved differences with Genentech (DNA) and two Rhode Island agencies, Rhode Island Partnership for Science and Technology and Industrial Recreational Building Authority. The company said it was relieved of the obligation to...
BioCentury | Feb 7, 2000
Company News

CytoTherapeutics management update

CytoTherapeutics Inc. (CTII), Sunnyvale, Calif. Business: Gene/Cell therapy Transition: George Dunbar becomes acting president and CEO, replacing Richard Rose, while remaining acting president of CTII's StemCells Inc. subsidiary Hired: Iris Brest as general counsel, formerly...
BioCentury | Jan 24, 2000
Finance

C'est la vie

...it will appeal. BTGC closed Friday at $15.063 up $1.75 (13 percent) on the week. CytoTherapeutics...
BioCentury | Jan 24, 2000
Tools & Techniques

Cubist: Antibiotic validation

...monoclonal antibodies to isolate human neural stem cells. StemCells (Sunnyvale, Calif.) is a subsidiary of CytoTherapeutics Inc....
Items per page:
1 - 10 of 109